Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Working Capital Changes: 2020-2024

Historic Other Working Capital Changes for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $1.7 million.

  • Xeris Biopharma Holdings' Other Working Capital Changes rose 3424.52% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 55.55%. This contributed to the annual value of $1.7 million for FY2024, which is 77.81% down from last year.
  • Xeris Biopharma Holdings' Other Working Capital Changes amounted to $1.7 million in FY2024, which was down 77.81% from $7.5 million recorded in FY2023.
  • Xeris Biopharma Holdings' Other Working Capital Changes' 5-year high stood at $7.5 million during FY2023, with a 5-year trough of -$3.3 million in FY2021.
  • Its 3-year average for Other Working Capital Changes is $4.4 million, with a median of $3.9 million in 2022.
  • In the last 5 years, Xeris Biopharma Holdings' Other Working Capital Changes plummeted by 255.68% in 2021 and then skyrocketed by 218.15% in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' Other Working Capital Changes (Yearly) stood at -$925,000 in 2020, then plummeted by 255.68% to -$3.3 million in 2021, then spiked by 218.15% to $3.9 million in 2022, then surged by 93.93% to $7.5 million in 2023, then slumped by 77.81% to $1.7 million in 2024.